mavorixafor (Xolremdi)
(Redirected from XOLREMDI)
Jump to navigation
Jump to search
Indications
- treatment of Whim syndrome in patients >= 12 years of age
Mechanism of action
- selective CXCR4 antagonist
- increases circulating neutrophils & lymphocytes to reduce risk of infection
More general terms
References
- ↑ Ingram I FDA Approves First Drug for WHIM Syndrome CXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes to reduce infections. https://www.medpagetoday.com/allergyimmunology/allergy/109871
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11256587
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10126019
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11233382
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71576687
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=138756132
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=78357868